It does not require multi-polymers, does not induce advanced thrombosis, and may reduce the time of double antiplatelet therapy. Therefore, it is difficult for DES treatment, such as small blood vessels, anatomically curved blood vessels, diffuse long lesions, bifurcation lesions, and oral lesions，DEB is an alternative method.
DEB still has some shortcomings: it cannot solve the elastic retraction of blood vessels in the acute phase. The severe dissection after balloon expansion affects blood flow or acute vascular occlusion, and it is still necessary to urgently place a stent at this time. In addition, after the insertion of DES, it is indeed superior to DEB in the largest lumen inner diameter. With continuous upgrading, the treatment and safety of new products are continuously improved, and the long-term efficacy may be better than DEB.
In conclusion, the feasibility, safety and effectiveness of DEB in the treatment of coronary artery disease, whether it is in-stent restenosis or primary disease, have been initially confirmed. Has advantages, therefore, DEB is likely to become a more optimized interventional treatment method.